2 insiders at Telix Pharmaceuticals Limited (TLX) reported open-market stock purchases totaling $1,016,736 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Behrenbruch Christian (director, officer: MD & Group CEO), who acquired 34,500 shares at $14.48 on April 28, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-09-07 | Smith Darren Charlton | officer: Group Chief Financial Officer | 2,071 | $9.66 | $19,998 | SEC Form 4 |
| 2026-04-29 | Behrenbruch Christian | director, officer: MD & Group CEO | 33,435 | $14.87 | $497,178 | SEC Form 4 |
| 2026-04-28 | Behrenbruch Christian | director, officer: MD & Group CEO | 34,500 | $14.48 | $499,560 | SEC Form 4 |
Telix Pharmaceuticals Limited is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $4.3B, with shares trading near $12.83.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.